etigilimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
etigilimab

GtoPdb Ligand ID: 13984

Synonyms: OMP-313M32

Compound class: Antibody

Comment: Etigilimab (OMP-313M32) is an anti-TIGIT monoclonal antibody [1]. Blocking the TIGIT/PVR interaction is proposed to promote anti-tumour immunity. This mechanism is proposed to be used in conjunction with anti-PD/1/PD-L1 immuno-oncology therapeutics, to further enhance the anti-tumour immune response.

References
1. Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. (2022) A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res, 28 (5): 882-892. [PMID:34844977]
2. Rousseau A, Parisi C, Barlesi F. (2023) Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open, 8 (2): 101184. [PMID:36933320]

References

1. Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. (2022)
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res, 28 (5): 882-892. [PMID:34844977]

2. Rousseau A, Parisi C, Barlesi F. (2023)
Anti-TIGIT therapies for solid tumors: a systematic review.
ESMO Open, 8 (2): 101184. [PMID:36933320]